Mark P. Labrecque

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

Mark P. Labrecque, Ilsa M. Coleman, Lisha G. Brown et al. · Journal of Clinical Investigation · 2019 · 468 citations · Full text

Medicine, Oncology, Urology +17

Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer

Diana C. DeLucia, Thomas M. Cardillo, Lisa S. Ang et al. · Clinical Cancer Research · 2020 · 86 citations · Full text

Medicine, Oncology, Pharmacology +17

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Dae‐Hwan Kim, Duanchen Sun, William K. Storck et al. · Clinical Cancer Research · 2021 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts

Hung‐Ming Lam, Holly M. Nguyen, Mark P. Labrecque et al. · European Urology · 2019 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer

Mark P. Labrecque, Lisha G. Brown, Ilsa M. Coleman et al. · Cancer Research · 2021 · 53 citations · Full text

Medicine, Molecular Biology, Oncology +16